Did the update include any new milestones or partnerships for the drug delivery platform that could affect growth forecasts?

Answer to the question

The half‑year 2025 results release from Innocan Pharma did not flag any new development‑stage milestones, licensing agreements or strategic partnerships for its drug‑delivery platform. The press release is confined to financial performance (revenue, net loss, cash balance, etc.) and provides only a continuation of existing R&D programmes, without adding fresh catalysts that would materially lift the company’s growth outlook.

Implications for the trade

• Fundamentals: With no fresh partnership or milestone to accelerate the platform’s trajectory, the forward‑looking revenue assumptions remain unchanged. The current cash runway and burn‑rate continue to be the primary drivers of the share‑price ceiling, keeping the stock’s upside limited to organic progress on the existing pipeline.
• Technical view: The stock is still trading near its six‑month downtrend channel (≈ 25 % below the 2024 H1 high). In the absence of a new catalyst, a break above the channel’s upper resistance (≈ CAD 0.30) would be the most bullish technical signal; otherwise, the price is likely to test the lower trend line (≈ CAD 0.21) before any rebound.
• Actionable recommendation: Until a definitive partnership or milestone is announced, maintain a neutral‑to‑defensive stance. Consider a small‑position pull‑back near the lower trend line if you are risk‑averse, or a modest buy on a breakout if the price breaches CAD 0.30 with volume confirmation. Keep the stop just below the lower trend line to protect against further downside.